磷酸依托泊苷(Etoposide Phosphate) - 药物靶点：Top II_在研适应症：急性髓性白血病，去势抵抗性前列腺癌，绒毛膜癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Etopofos、Etoposide phosphate (USAN)

+ [2]

靶点

Top II

作用方式

抑制剂

作用机制

Top II抑制剂(拓扑异构酶II抑制剂)

治疗领域

肿瘤免疫系统疾病内分泌与代谢疾病+ [4]

在研适应症

急性髓性白血病去势抵抗性前列腺癌绒毛膜癌+ [6]

非在研适应症-

原研机构

Bristol Myers Squibb Co.

在研机构

CHEPLAPHARM Arzneimittel GmbH

非在研机构-

权益机构

CHEPLAPHARM Arzneimittel GmbH

Bristol Myers Squibb Co.

最高研发阶段批准上市

首次获批日期

美国 (1996-05-17),

小细胞肺癌睾丸肿瘤

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C29H33O16P

InChIKeyLIQODXNTTZAGID-OCBXBXKTSA-N

CAS号117091-64-2

关联

61

项与磷酸依托泊苷相关的临床试验

NCT06905509

/ Not yet recruiting临床2期IIT

A Phase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy Pre-Autologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL)

This phase II trial tests how well epcoritamab in combination with standard of care (SOC) platinum-based chemotherapy (rituximab, ifosfamide, carboplatin, etoposide [RICE], rituximab, cytarabine, dexamethasone, oxaliplatin or carboplatin RDHAP/X] or gemcitabine and oxaliplatin [Gem/Ox]) and autologous hematopoietic cell transplant (HCT) works in treating patients with large B-cell lymphoma (LBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Epcoritamab, a type of bispecific T-cell engager, binds to a protein called CD3, which is found on T cells (a type of white blood cell). It also binds to a protein called CD20, which is found on B cells (another type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs, such as ifosfamide, etoposide phosphate, cytarabine, and gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. An autologous HCT is a procedure in which blood-forming stem cells (cells from which all blood cells develop) are removed, stored, and later given back to the same person. Giving epcoritamab in combination with SOC platinum-based chemotherapy, such as RICE, RDHAP/X and Gem/Ox, and autologous HCT may kill more cancer cells in patients with relapsed or refractory LBCL.

开始日期2025-08-01

申办/合作机构

University of California, Davis

[+1]

NCT06942039

/ Not yet recruiting早期临床1期

A Pilot Study of Intrathecal Topotecan and Maintenance Chemotherapy in the Post-consolidation Setting for the Treatment of High-risk Embryonal Central Nervous System Tumours in Children Less Than 6 Years of Age

Pilot study to determine feasibility of adding intrathecal chemotherapy and maintenance therapy after high dose chemotherapy for treatment of newly diagnosed HR-EBTs in patients less than 6 years of age.

开始日期2025-06-01

申办/合作机构

C17 Council

NCT06356883

/ Recruiting临床2期

A Randomized Phase II Study on Intraarterial Carboplatin Combined With Caelyx Compared to Intraarterial Carboplatin Combined With Etoposide Phosphate for Progressing Glioblastoma at First or Second Relapse

The standard of care for glioblastoma (GBM) treatment involves maximal resection followed by concomitant radiotherapy and temozolomide. Progression-free survival (PFS) with this treatment is only 6.9 months and relapse is inevitable. At relapse, there is no consensus regarding the optimal therapeutic strategy. The rationale behind the fact that limited chemotherapy agents are available in the treatment of malignant gliomas is related to the blood-brain barrier (BBB), which impedes drug entry to the brain. Intraarterial (IA) chemotherapy allows to circumvent this. Using IA delivery of carboplatin, can produce responses in 70% of patients for a median PFS of 5 months. Median survival from study entry was 11 months, whereas the overall survival (OS) 23 months. How can the OS and PFS be improved? By combining chemotherapeutic agents with different mechanisms of action.
Study design: In this phase II trial, treatment will be offered at relapse. Surgery will be performed for cytoreduction if it is warranted, followed with a combination IA carboplatin + IA Cealyx (liposomal doxorubicin) or IA carboplatin + IA etoposide phosphate. Toxicity will be assessed according to the NCIC common toxicity criteria. Treatment will consist in either IA carboplatin (400 mg/m^2) + IA Cealyx (30 mg/m^2) or IA carboplatin (400 mg/m^2) + IA etoposide phosphate (400 mg/m^2) every 4-6 weeks (1 cycle). Up to twelve cycles will be offered.
Outcome measurements: Tumor response will be evaluated using the RANO criteria by magnetic resonance imaging monthly. Primary outcome will PFS and tumor response. Secondary outcome will include median OS, toxicity, quality of life (QOL), neurocognition (NC).
Putting together these data will allow to correlate clinical and radiological response to QOL and NC.

开始日期2024-12-01

申办/合作机构

University of Sherbrooke

100 项与磷酸依托泊苷相关的临床结果

登录后查看更多信息

100 项与磷酸依托泊苷相关的转化医学

登录后查看更多信息

100 项与磷酸依托泊苷相关的专利（医药）

登录后查看更多信息

257

项与磷酸依托泊苷相关的文献（医药）

2025-04-01·Journal of Oncology Pharmacy Practice

Successful desensitization to etoposide in a patient after cardiac arrest

Article

作者: Pérez-Codesido, S. ; Jandus, P. ; Azzi Virgini, V. ; Fertani, S.

IntroductionEtoposide phosphate is a chemotherapeutic agent used to treat various malignant neoplasms. Hypersensitivity reactions may occur with its use, and in rare cases, an anaphylactic reaction can manifest. Available options for patients experiencing hypersensitivity reactions include premedication, changing treatment, or undergoing desensitization. Various pediatric desensitization protocols have been described, ranging from six to fifteen steps, while published adult cases are rare.Case ReportWe report the case of a 61-year-old woman with small-cell lung cancer and brain metastases. In November 2019, she underwent the second cycle of cisplatin and etoposide phosphate treatment. While receiving etoposide phosphate, she experienced dyspnea and suffered a cardiorespiratory arrest, leading to cardiopulmonary resuscitation and subsequent admission to the Intensive Care Unit. Her acute tryptase levels were notably elevated at 18 µg/L (compared to a baseline tryptase level of 6,6 µg/L) during the reaction.Case ManagementWe implemented a 16-step desensitization protocol (without premedication) under close monitoring in an intermediate care unit. The protocol was successfully executed over three cycles until tumor progression mandated a modification in systemic treatment.DiscussionTo our knowledge, this is the first documented case of successful desensitization to etoposide phosphate in a patient who experienced cardiac arrest during a hypersensitivity reaction. Although protocols of varying lengths have been published, we emphasize the importance of individualizing each protocol to fit the severity of the reaction and the resources and experience of each unit.

2024-06-01·Methods

Multi-omics data integration and drug screening of AML cancer using Generative Adversarial Network

Article

作者: Afroz, Sabrin ; Habib, Md Ahsan ; Ashad Alam, Md ; Reza, Md Selim ; Islam, Nadira

In the era of precision medicine, accurate disease phenotype prediction for heterogeneous diseases, such as cancer, is emerging due to advanced technologies that link genotypes and phenotypes. However, it is difficult to integrate different types of biological data because they are so varied. In this study, we focused on predicting the traits of a blood cancer called Acute Myeloid Leukemia (AML) by combining different kinds of biological data. We used a recently developed method called Omics Generative Adversarial Network (GAN) to better classify cancer outcomes. The primary advantages of a GAN include its ability to create synthetic data that is nearly indistinguishable from real data, its high flexibility, and its wide range of applications, including multi-omics data analysis. In addition, the GAN was effective at combining two types of biological data. We created synthetic datasets for gene activity and DNA methylation. Our method was more accurate in predicting disease traits than using the original data alone. The experimental results provided evidence that the creation of synthetic data through interacting multi-omics data analysis using GANs improves the overall prediction quality. Furthermore, we identified the top-ranked significant genes through statistical methods and pinpointed potential candidate drug agents through in-silico studies. The proposed drugs, also supported by other independent studies, might play a crucial role in the treatment of AML cancer. The code is available on GitHub; https://github.com/SabrinAfroz/omicsGAN_codes?fbclid=IwAR1-/stuffmlE0hyWgSu2wlXo6dYlKUei3faLdlvpxTOOUPVlmYCloXf4Uk9ejK4I.

2024-04-13·Cureus

E-cigarette-/Vape-Associated Lung Injury as a Cause of Interstitial Lung Disease

作者: Boscia, Joseph ; Vess, Kathryn B ; Ivan, Nicole

E-cigarette-/vape-associated lung injury (EVALI) refers to damage to lung tissue occurring as a result of e-cigarette utilization or via vaping of inhaled nicotine products. Vaping refers to the practice of inhaling an aerosol derived from heating a liquid or gas containing substances such as nicotine, cannabinoids, flavoring, or additives. Battery-operated e-cigarettes or vape pens are the vessels commonly used in this practice. EVALI, first described in the literature in 2019, has a non-specific course, presenting initially with cough and dyspnea. It can progress, however, to interstitial lung disease or result in damage to the lung parenchyma with concomitant inflammation and fibrosis. Imaging findings reflect the development of this inflammation and fibrosis, often visualized as ground-glass opacities on computed tomography (CT) scans. Formal biopsies are not required to make the diagnosis of EVALI, and thus, a gap exists in the scientific literature with regard to the pathology of lungs exposed to non-tetrahydrocannabinol (THC) e-cigarettes. The following case details the clinical course of a 62-year-old male who presented to the outpatient pulmonology office with symptomology and exposure history consistent with EVALI, unique in presentation due to the timeline of his disease development. The patient initially presented to the clinic for the evaluation of a non-productive cough and exertional dyspnea beginning one year ago, with an associated new home oxygen requirement of 2 liters via nasal cannula. The patient's past medical history was relevant for diffuse large B-cell lymphoma treated with the chemotherapeutic regimen that consists of etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab, commonly known as EPOCH-R, as well as a social history relevant for a 35-pack-year smoking history. On further questioning, the patient revealed that following cessation of cigarette smoking, he began using non-THC e-cigarettes daily and had been doing so for 10 years prior to symptom onset. Imaging and biopsy findings consisted of a CT of the chest demonstrating concern for interstitial lung disease and an open lung biopsy demonstrating diffuse alveolar damage with eosinophilia. Given the patient's history, clinical symptoms, and imaging findings, a diagnosis of EVALI was established. This case was documented not only to increase awareness of the rising incidence of EVALI as the use of e-cigarettes and vapes becomes increasingly popular but also to further understand the inhalational injury sustained from non-THC e-cigarettes and other inhalational practices.

100 项与磷酸依托泊苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04107	磷酸依托泊苷	L01CB01	DBSALT000070

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性髓性白血病	瑞士	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
去势抵抗性前列腺癌	中国	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
绒毛膜癌	瑞士	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
胚胎癌	瑞士	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
霍奇金淋巴瘤	巴西	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
淋巴瘤	日本	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
非霍奇金淋巴瘤	巴西	CHEPLAPHARM Arzneimittel GmbH	2018-10-09
小细胞肺癌	美国	CHEPLAPHARM Arzneimittel GmbH	1996-05-17
睾丸肿瘤	美国	CHEPLAPHARM Arzneimittel GmbH	1996-05-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03113500 (CTgov)	临床2期	成人T细胞白血病/淋巴瘤 \| 外周T细胞淋巴瘤 \| 间变性大细胞淋巴瘤 \| 肝脾 T 细胞淋巴瘤 \| ALK阳性间变性大细胞淋巴瘤 \| 免疫母细胞性淋巴结病 \| 肠病相关的T细胞淋巴瘤	48	Laboratory Biomarker Analysis+Etoposide+cyclophosphamide+Etoposide Phosphate+Prednisone+Doxorubicin+Brentuximab Vedotin	鹹憲鹹齋襯糧襯齋網淵(艱範廠蓋蓋願鹹獵範範) = 憲網製獵鏇觸廠網醖夢鏇壓製壓構築醖觸醖鹹 (鏇齋簾顧構窪網膚醖糧, 鹽築構齋簾糧壓襯積淵 ~ 鏇夢繭窪獵簾夢蓋築衊) 更多	-	2023-04-19
NCT02306161 (CTgov)	临床3期	继发性肺恶性肿瘤 \| 外周性原始神经外胚层肿瘤 \| 尤文肉瘤 \| 骨转移癌	312	Stereotactic Radiosurgery+Etoposide+Cyclophosphamide+Etoposide Phosphate+Doxorubicin+Ifosfamide+Vincristine (Regimen A (VDC/IE))	(築憲鹹製窪壓製鑰壓齋) = 憲夢選夢醖衊夢蓋醖鏇選廠窪廠夢觸艱壓艱壓 (願壓淵艱廠淵襯艱網衊, 鏇獵鏇膚廠壓廠醖鬱築 ~ 餘遞蓋遞醖夢糧網願繭) 更多	-	2022-07-01
NCT02306161 (CTgov)	临床3期	继发性肺恶性肿瘤 \| 外周性原始神经外胚层肿瘤 \| 尤文肉瘤 \| 骨转移癌	312	Stereotactic Radiosurgery+Etoposide+Ganitumab+cyclophosphamide+Etoposide Phosphate+Doxorubicin+Ifosfamide+Vincristine (Regimen B (VDC/IE + Ganitumab))	(築憲鹹製窪壓製鑰壓齋) = 淵願製窪壓艱鏇膚選築選廠窪廠夢觸艱壓艱壓 (願壓淵艱廠淵襯艱網衊, 醖餘窪醖鑰願鬱繭遞襯 ~ 遞願餘範範積窪範蓋觸) 更多	-	2022-07-01
NCT01042522 (NRG oncology/gynecologic oncology group study14, CTgov)	临床2期	卵巢颗粒细胞瘤 \| 卵巢性腺母细胞瘤 \| 卵巢雄激素瘤	63	Laboratory Biomarker Analysis+Carboplatin+Paclitaxel (Arm I (Paclitaxel, Carboplatin))	(鑰餘鬱願構襯鏇構廠艱) = 鑰選壓製積網網觸壓鏇顧遞觸鑰顧築簾糧窪壓 (艱鹹製憲窪顧憲衊鹹壓, 製網淵膚範獵築鹹鹽夢 ~ 淵製艱積顧鹹醖顧壓築) 更多	-	2022-01-25
	临床2期	卵巢颗粒细胞瘤 \| 卵巢性腺母细胞瘤 \| 卵巢雄激素瘤	63	Laboratory Biomarker Analysis+Etoposide Phosphate+cisplatin+Bleomycin Sulfate (Arm II (Bleomycin Sulfate, Etoposide Phosphate, Cisplatin))	(鑰餘鬱願構襯鏇構廠艱) = 餘夢膚鬱網衊艱網製觸顧遞觸鑰顧築簾糧窪壓 (艱鹹製憲窪顧憲衊鹹壓, 衊顧齋襯糧積糧夢鬱壓 ~ 製網願壓壓窪製夢構選) 更多	-	2022-01-25
NCT02137096 (CTgov)	临床3期	复发性鼻咽癌	1	Autologous Stem Cell Transplantation+Etoposide phosphate+Carboplatin+Ifosfamide	鏇鹽築壓製蓋壓願顧憲(餘鹹網網鏇積觸淵餘觸) = 醖淵願製選膚範顧鏇鹹膚願顧憲壓壓獵鹽廠壓 (衊製襯範蓋蓋糧艱壓蓋, 觸觸積鑰選餘觸艱製餘 ~ 鬱顧艱築餘鬱蓋範構襯) 更多	-	2019-06-24
NCT01256398 (CTgov)	临床2期	急性淋巴细胞白血病	66	In Vitro-Treated Peripheral Blood Stem Cell Transplantation+dasatinib+Mercaptopurine+Methotrexate+Alemtuzumab+Cytarabine+Fludarabine Phosphate+cyclophosphamide+Etoposide Phosphate+Leucovorin Calcium+Filgrastim+Melphalan+Tacrolimus+Dexamethasone+Vincristine Sulfate+Daunorubicin Hydrochloride	築壓鏇積製鬱鹽構鹽蓋(獵鬱鬱壓範鬱夢廠獵獵) = 積範製餘齋淵遞糧鑰餘鑰蓋壓網鑰衊餘積鹹膚 (鑰膚築觸膚築選顧淵顧, 廠壓選選範夢鏇製衊壓 ~ 鏇獵鹹膚夢壓繭鏇築齋) 更多	-	2019-05-21
NCT01175356 (CTgov)	临床1期	神经节成神经细胞瘤	99	In Vitro-Treated Peripheral Blood Stem Cell Transplantation+Iobenguane I-131+Doxorubicin Hydrochloride+Busulfan+Cyclophosphamide+Etoposide Phosphate+Melphalan+Isotretinoin+cisplatin+Topotecan Hydrochloride+Vincristine Sulfate	繭衊艱憲遞憲觸鹽鏇觸(顧網積獵積築艱觸觸鹽) = 餘願獵觸構膚網遞願餘積顧淵鑰壓艱廠築選網 (製選選衊選鹽製糧蓋壓, 顧糧糧衊淵範鹹積窪醖 ~ 憲觸願繭鏇築顧鑰繭觸) 更多	-	2017-09-28
NCT00302003 (CTgov)	临床3期	霍奇金淋巴瘤 \| 小儿结节性硬化霍奇金淋巴瘤	287	radiation therapy+cyclophosphamide+etoposide phosphate+prednisone+Filgrastim+doxorubicin hydrochloride+vinorelbine tartrate+ifosfamide+cisplatin+dexamethasone+vincristine sulfate+Cytarabine	淵願蓋夢襯築襯襯夢襯(觸鏇鏇齋鹹鏇衊鬱窪築) = 選鹹製膚窪餘顧構獵餘憲簾範膚膚醖獵鬱壓鏇 (積鏇範遞鹽顧鏇網窪製, 憲艱餘壓衊願鬱廠夢願 ~ 壓鹹艱廠繭壓窪鏇衊蓋) 更多	-	2017-02-09
NCT01969435 (CTgov)	临床2期	霍奇金淋巴瘤 \| 非霍奇金淋巴瘤	50	Etoposide phosphate+Carmustine+Melphalan HCl (propylene glycol-free)+Cytarabine	襯襯衊選鹹觸壓壓窪廠(鬱遞衊構糧衊鹹願壓鏇) = 範構艱觸鹽衊觸鹹製觸艱構廠鹹積鹹觸觸醖範 (願鹹築醖網範憲獵憲齋, 築觸顧襯構餘遞製廠醖 ~ 襯糧範夢襯鬱簾蓋鹽壓) 更多	-	2016-11-11